Skip to main content

Picard Medical, Inc.

corporate_fare Company Profile

Picard Medical, Inc.

PMI·NYSE·Industrial Applications And Services·CIK 0002030617

Picard Medical, Inc. is a Delaware-incorporated holding company that owns 100% of the membership interests of SynCardia Systems, LLC; its business operations are carried out through SynCardia. SynCardia is a medical technology company that manufactures and sells the only U.S. Food and Drug Administration and Health Canada approved Total Artificial Heart ("TAH"), which fully replaces the function of a failing human heart. To date, more than 2,100 SynCardia TAHs have been implanted in patients across 27 countries, and the SynCardia TAH is an established bridge to heart transplantation ("BTT") for patients with biventricular heart failure, also referred to as end-stage heart failure, in the United States and around the globe. SynCardia is also pursuing additional research and advancements in medical technology, including the next-generation, fully implantable and driver-less heart, the Emperor TAH; both the SynCardia and Emperor TAH are subject to additional development and regulatory review. The currently approved SynCardia TAH System consists of an implant including left and right artificial ventricles, external pneumatic drivers that power the implant, and drivelines that connect the external driver to the implant. The implantation procedure follows routine surgical techniques used by cardiothoracic surgeons performing heart transplantation. The system provides immediate and complete cardiac output by replacing both ventricles and all four heart valves. The SynCardia TAH is powered by pneumatic drivers available for in-hospital use, the Companion 2 Driver ("C2 Driver"), and for in-home use, the Freedom Driver. These systems generate true pulsatile flow using a redundant pneumatic pump assembly, restoring full hemodynamics and giving patients time to stabilize, recover, and ultimately receive a heart transplant.

Picard Medical, Inc. (NYSE:PMI) is a publicly traded company in the Industrial Applications And Services sector. Wiseek has independently scored 4 items for PMI at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-11-16, rated 9/10. Across its 4 most recent items scored 7 or higher, the top rating is 9/10, with 1 rated 8 or above. Recent SEC coverage for PMI spans 10-Q, S-3/A, PRE 14A, 8-K.

Recent high-impact activity:

  • Picard Medical Q3: Going-Concern Warning With $67K Cash and Zero Product Revenue
  • Picard Registers Resale of 500,000 Shares Tied to $1.0M Convertible Notes
  • Picard Medical Seeks Votes on $5M Private Placement and Expanded Equity Plan
  • Picard Medical Names Richard Fang Permanent CEO; Discloses $1.2M in Related-Party Loans

Financial Snapshot

Fiscal year ended December 31, 2025
Revenue
$4.94M
Net Income
-$27M
Op. Cash Flow
-$15.67M
Gross Profit
-$204K
Operating Income
-$13.26M
Cash & Equivalents
$7.45M
Total Debt
$5.45M
Debt / Equity
1.44×
Net Margin
-5.47×
Shares Outstanding
73.7M sh
Source: 10-K · filed 2026-05-14 · accession 0001437749-26-017171

Short Interest & Short Volume

1.00 days to cover

FINRA reported short interest of 74,420 shares in PMI as of the October 30, 2026 settlement, a 44.9% increase from the prior period — about 1.0 days to cover at its recent average daily volume. On November 20, 2026, 46.1% of PMI volume reported to FINRA trade-reporting facilities was marked short.

Short interest (bi-monthly positions)74,420 shares as of October 30, 2026
Change vs prior period▲ 44.9%
Days to cover1.00 at avg daily volume of 410,772
Daily short volume (FINRA facilities)46.1% of 11,591 shares on November 20, 2026
5-day average short volume57.9%

Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.

Dilution Risk

Low risk

Filing-implied dilution signals for PMI, detected from its recent SEC filings · based on capital-structure filings through 2026-11-10.

1 shelf registration

Resale Prospectus Filed for 500,000 Shares · No Company Proceeds From Resales

A filing-implied signal, not a realized share count. How Wiseek tracks dilution →

Browse all tickers starting with P →
$6.79 -0.03% today
52-week range · as of 2026-11-16 $2.65 – $208
Market cap
$18.07M
Volume
20.3K (0.1× avg)
3-mo avg 286.8K
Live data · 2026-11-21 05:47 UTC · Market closed

show_chartPrice Chart

Loading chart...

feed PMI - Latest Insights

PMI
Nov 16, 2026, 5:30 PM EST
Filing Type: 10-Q
Importance Score:
9
Price at Filing: $7.24
Real-time Price: $6.79 info
Change: -$0.4519 (-6%) info
Market Cap: $18.072M info
PMI
Nov 05, 2026, 4:18 PM EST
Filing Type: S-3/A
Importance Score:
7
Price at Filing: $7.85
Real-time Price: $6.79 info
Change: -$1.06 (-14%) info
Market Cap: $18.072M info
PMI
Nov 03, 2026, 5:24 PM EST
Filing Type: PRE 14A
Importance Score:
7
Price at Filing: $7.48
Real-time Price: $6.79 info
Change: -$0.6919 (-9%) info
Market Cap: $18.072M info
PMI
Nov 03, 2026, 5:21 PM EST
Filing Type: 8-K
Importance Score:
7
Price at Filing: $7.48
Real-time Price: $6.79 info
Change: -$0.6919 (-9%) info
Market Cap: $18.072M info
Research tools: Filing Impact Index Dilution Tracker Split Calendar Open Datasets